Pharmacoproteomics and toxicoproteomics: The field of dreams

Journal of Proteomics

Volumn 74, Issue 12, 2011, Pages 2549-2553

  Yu, Li Rong ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Biomarker; Drug development; Mechanism of action; Nanotechnology; Pharmacoproteomics; Toxicoproteomics

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; NANOMATERIAL; PROTEIN; TOXIN; VACCINE;

AFFINITY CHROMATOGRAPHY; CELLULAR DISTRIBUTION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; INFECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLITE; MICROPARTICLE ENZYME IMMUNOASSAY; MOLECULE; MULTIPLE REACTION MONITORING; NANOTECHNOLOGY; NEOPLASM; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHARMACOLOGY; PHARMACOPROTEOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEOMICS; REACTION ANALYSIS; TOXICITY TESTING; TOXICOLOGY; TOXICOPROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEOMICS; TOXICOLOGY;

EID: 81055124249     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.10.001     Document Type: Editorial

References (43)

1. Hamburg M.A., Collins F.S. The path to personalized medicine. N Engl J Med 2010, 363:301-304.
2. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther 2007, 81:164-169.
3. Shawver L.K., Slamon D., Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1:117-123.
4. Yu L.R., Issaq H.J., Veenstra T.D. Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets. Proteomics Clin Appl 2007, 1:1042-1057.
5. Luesch H. Towards high-throughput characterization of small molecule mechanisms of action. Mol Biosyst 2006, 2:609-620.
6. Zhang Q.Y., Mao J.H., Liu P., Huang Q.H., Lu J., Xie Y.Y., et al. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A 2009, 106:3378-3383.
7. Schrattenholz A., Groebe K., Soskic V. Systems biology approaches and tools for analysis of interactomes and multi-target drugs. Methods Mol Biol 2010, 662:29-58.
8. Gonzalez-Angulo A.M., Hennessy B.T., Mills G.B. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 2010, 28:2777-2783.
9. Mendrick D.L. Transcriptional profiling to identify biomarkers of disease and drug response. Pharmacogenomics 2011, 12:235-249.
10. Moller A., Soldan M., Volker U., Maser E. Two-dimensional gel electrophoresis: a powerful method to elucidate cellular responses to toxic compounds. Toxicology 2001, 160:129-138.
11. Bandara L.R., Kennedy S. Toxicoproteomics - a new preclinical tool. Drug Discov Today 2002, 7:411-418.
12. Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers 2002, 7:269-290.
13. Witzmann F.A., Grant R.A. Pharmacoproteomics in drug development. Pharmacogenomics J 2003, 3:69-76.
14. Wetmore B.A., Merrick B.A. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol Pathol 2004, 32:619-642.
15. Dowling V.A., Sheehan D. Proteomics as a route to identification of toxicity targets in environmental toxicology. Proteomics 2006, 6:5597-5604.
16. Monsinjon T., Knigge T. Proteomic applications in ecotoxicology. Proteomics 2007, 7:2997-3009.
17. Arrell D.K., Niederlander N.J., Perez-Terzic C., Chung S., Behfar A., Terzic A. Pharmacoproteomics: advancing the efficacy and safety of regenerative therapeutics. Clin Pharmacol Ther 2007, 82:316-319.
18. Butler G.S., Overall C.M. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labeling and tandem mass spectrometry. Curr Pharm Des 2007, 13:263-270.
19. Jain K.K. Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 2004, 5:331-336.
20. D'Alessandro A., Zolla L. Pharmacoproteomics: a chess game on a protein field. Drug Discov Today 2010, 15:1015-1023.
21. Gao Y., Holland R.D., Yu L.R. Quantitative proteomics for drug toxicity. Brief Funct Genomic Proteomic 2009, 8:158-166.
22. Han M.H., Hwang S.I., Roy D.B., Lundgren D.H., Price J.V., Ousman S.S., et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451:1076-1081.
23. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
24. Sleno L., Emili A. Proteomic methods for drug target discovery. Curr Opin Chem Biol 2008, 12:46-54.
25. Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., et al. Predicting new molecular targets for known drugs. Nature 2009, 462:175-181.
26. Koutsoukas A., Simms B., Kirchmair J., Bond P.J., Whitmore A.V., Zimmer S., et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics 2011, 74:2554-2574.
27. Cohen A.A., Geva-Zatorsky N., Eden E., Frenkel-Morgenstern M., Issaeva I., Sigal A., et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 2008, 322:1511-1516.
28. Millard M., Pathania D., Shabaik Y., Taheri L., Deng J., Neamati N. Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity. PLoS One 2010, 5:e13131. 10.1371/journal.pone.0013131.
29. Li X.-H., Li C., Xiao Z.-Q. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer. J Proteomics 2011, 74:2642-2649.
30. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics 2001, 69:89-95.
31. Benninghoff A.D. Toxicoproteomics-the next step in the evolution of environmental biomarkers. Toxicol Sci 2007, 95:1-4.
32. Hinman L.M., Carl K.M., Spear B.B., Salerno R.A., Becker R.L., Abbott B.M., et al. Development and regulatory strategies for drug and diagnostic co-development. Pharmacogenomics 2010, 11:1669-1675.
33. Goodsaid F.M., Mendrick D.L. Translational medicine and the value of biomarker qualification. Sci Transl Med 2010, 2:47ps44.
34. Hennessy B.T., Lu Y., Poradosu E., Yu Q., Yu S., Hall H., et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007, 13:7421-7431.
35. Andersen J.N., Sathyanarayanan S., Di Bacco A., Chi A., Zhang T., Chen A.H., et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010, 2:43ra55.
36. Meng Z., Veenstra T.D. Targeted mass spectrometry approaches for protein biomarker verification. J Proteomics 2011, 74:2650-2659.
37. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
38. Li J., Kelm K.B., Tezak Z. Regulatory perspective on translating proteomic biomarkers to clinical diagnostics. J Proteomics 2011, 74:2682-2690.
39. Reyzer M.L., Caprioli R.M. MALDI-MS-based imaging of small molecules and proteins in tissues. Curr Opin Chem Biol 2007, 11:29-35.
40. Greer T., Sturm R., Li L. Mass spectrometry imaging for drugs and metabolites. J Proteomics 2011, 74:2617-2631.
41. Ray S., Reddy P.J., Choudhary S., Raghu D., Srivastava S. Emerging nanoproteomics approaches for disease biomarker detection: a current perspective. J Proteomics 2011, 74:2660-2681.
42. Thomas C.R., George S., Horst A.M., Ji Z., Miller R.J., Peralta-Videa J.R., et al. Nanomaterials in the environment: from materials to high-throughput screening to organisms. ACS Nano 2011, 5:13-20.
43. Adamczyk-Poplawska M., Markowicz S., Jagusztyn-Krynicka E.K. Proteomics for development of vaccine. J Proteomics 2011, 74:2596-2616.